Melinda Jezierski, MD
Family Medicine · Santa Maria, CANPI 1487868154
Payments from drug & device makers
Across 356 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$847
- AbbVie$809
- Pfizer$753
- GSK$507
- Boehringer Ingelheim$418
- Lilly USA, LLC$335
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,586100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 59 | $847 |
| AbbVie(2 entities) | 45 | $809 |
| Pfizer | 50 | $753 |
| GSK | 46 | $507 |
| Boehringer Ingelheim | 19 | $418 |
| Lilly USA, LLC | 28 | $335 |
| Novo Nordisk | 29 | $334 |
| Bayer | 14 | $182 |
| AstraZeneca | 12 | $179 |
| Biohaven Pharmaceuticals, Inc. | 3 | $163 |
| Novartis | 6 | $141 |
| Inspire Medical Systems, Inc. | 1 | $127 |
| Johnson & Johnson | 7 | $97 |
| Dexcom, Inc. | 3 | $86 |
| Corcept Therapeutics | 3 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Merck | 4 | $48 |
| Exact Sciences | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Abbott | 2 | $41 |
| Mannkind Corporation | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Boston Scientific | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $11 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,604 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 181 | $230,297 |
| OzempicSemaglutide | 129 | $159,096 |
| EliquisApixaban | 83 | $84,235 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $73,210 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 38 | $53,546 |
| TradjentaLinagliptin | 35 | $42,011 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 17 | $41,408 |
| XareltoRivaroxaban | 29 | $33,143 |
| MounjaroTirzepatide | 28 | $31,556 |
| Teriparatide | 11 | $29,779 |
| TrulicityDulaglutide | 25 | $27,681 |
| MyrbetriqMirabegron | 21 | $24,898 |
| FarxigaDapagliflozin Propanediol | 15 | $23,878 |
| Repatha SureclickEvolocumab | 17 | $16,587 |
| WegovySemaglutide | 12 | $15,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $418 | $286,159232 claims |
| Novo NordiskOzempic, Wegovy | $334 | $174,720141 claims |
| PfizerEliquis | $753 | $84,23583 claims |
| GSKTrelegy Ellipta | $507 | $73,21081 claims |
| MerckJanumet Xr, Belsomra | $48 | $64,40750 claims |
| Lilly USA, LLCMounjaro, Trulicity | $335 | $59,23753 claims |
| AmgenEvenity (2 Syringes) | $847 | $41,40817 claims |
| Johnson & JohnsonXarelto | $97 | $33,14329 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $24,89821 claims |
| AstraZenecaFarxiga | $179 | $23,87815 claims |
| AbbVieSynthroid | $809 | $2,36835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Santa Maria
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.